Search Results
Jun 03, 2026, 09:00 ET AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
enzyme inhibitors to 30 mg once daily. Consider dose reduction of CYP3A4 substrates when co-administering TAVNEOS. Co‑administration of avacopan and 40 mg simvastatin increases the systemic exposure of simvastatin. While taking TAVNEOS, limit simvastatin dosage to 10 mg daily (or 20 mg daily for patients
More news about: Amgen
Jun 03, 2026, 08:30 ET Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL. Please see full
More news about: Neurocrine Biosciences, Inc.
Jun 03, 2026, 08:04 ET TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
10.8mg/kg3
More news about: TransCode Therapeutics, Inc.
Jun 03, 2026, 03:11 ET Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
More news about: Lupin Pharmaceuticals, Inc.
Jun 03, 2026, 00:04 ET Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
52, a key secondary endpoint, 53.6% of patients receiving nipocalimab 15 mg/kg achieved an SRI-4b response, compared with 39.7% for placebo plus background medication.More patients receiving nipocalimab 15 mg/kg also achieved LLDASc, a key exploratory endpoint that enables
More news about: Johnson & Johnson
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
anti-Ro60 and/or anti-Ro52 immunoglobulin G (IgG) antibodies. 163 adults aged 18-75 were randomized 1:1:1 to receive intravenous nipocalimab at 5 or 15 mg/kg, or placebo every 2 weeks through Week 22 and received protocol-permitted background standard of care. Safety assessments were conducted through Week
More news about: Johnson & Johnson
Jun 02, 2026, 20:00 ET 2026 ASCO | 科倫博泰創新B7-H3 ADC SKB500首次人體研究數據公布
研究分為劑量遞增、劑量擴展及適應症拓展三個階段，共入組192例患者，包括小細胞肺癌(SCLC)、食管鱗狀細胞癌(ESCC)、頭頸部鱗狀細胞癌(HNSCC)、結直腸癌(CRC)、神經內分泌癌(NEC)及其他腫瘤。患者接受SKB500 2-18mg/kg Q3W 劑量范圍給藥，並在12mg/kg及16mg/kg進行了劑量擴展和適應症拓展。
More news about: 科倫博泰
Jun 02, 2026, 20:00 ET Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
neuroendocrine carcinoma (NEC), and other tumors. Patients received SKB500 at doses ranging from 2 to 18 mg/kg every three weeks (Q3W), with dose expansion and indication expansion conducted at 12 mg/kg and 16 mg/kg.
More news about: Kelun-Biotech
Jun 02, 2026, 16:45 ET Mês da Miastenia Gravis comemora recente aprovação da primeira terapia subcutânea com foco na melhora funcional e na qualidade de vida do paciente(1)
de Miastenia Gravis. Visão geral clínica da MG. Consultado em 11/12/2025. Disponível em https://myasthenia.org/Professionals/Clinical-Overview-of-MG.9 Kiessling P, et al. "The
More news about: UCB Biopharma
Jun 02, 2026, 15:30 ET Skyhawk Therapeutics annonce les résultats intermédiaires à douze mois de l'essai clinique de phases 1/2 de SKY-0515 dans le traitement de la maladie de Huntington
naturelle des patients symptomatiques pondérées par le score de propensionLes patients traités par SKY-0515 à une dose de 9 mg présentent une réduction de 69 % de la protéine huntingtine mutante (mHTT) au bout de douze moisLa société annonce également
More news about: Skyhawk Therapeutics
Jun 02, 2026, 13:02 ET VWCO fortalece seu portfólio na Colômbia com a chegada do Delivery 11.180 4x4
[email protected] - https://mma.prnewswire.com/media/2993346/MG_2464.jpg
More news about: Volkswagen Caminhões e Ônibus
Jun 02, 2026, 12:50 ET Skyhawk Therapeutics anuncia los resultados del ensayo clínico SKY-0515 en la enfermedad de Huntington
sintomáticos.Los pacientes tratados con SKY-0515 lograron reducciones del 69% de la proteína huntingtina mutante (mHTT) con la dosis de 9 mg a los doce meses.La compañía también anuncia que la parte de Australia y Nueva Zelanda (004-ANZ) de su estudio pivotal de
More news about: Skyhawk Therapeutics
Jun 02, 2026, 10:23 ET Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026
substantial clinical benefit observed following treatment with eganelisib in this study.Eganelisib was well tolerated at both dose levels (45 mg and 60 mg, once daily) with no dose-limiting toxicities and no intrinsic hematologic toxicity. This is consistent with the myeloid-restricted expression of
More news about: Stelexis BioSciences, Inc.
Jun 02, 2026, 10:02 ET Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Sunday, June 14th. The oral presentation will feature results from the Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in myelofibrosis.This abstract highlights the combination of selinexor plus ruxolitinib's ability to
More news about: Karyopharm Therapeutics Inc.
Jun 02, 2026, 09:30 ET Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.INDICATIONS FOR JAYPIRCA (pirtobrutinib)Jaypirca
More news about: Eli Lilly and Company
Jun 02, 2026, 08:59 ET Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
median selinexor dose was 51.7 mg/week and the median ruxolitinib dose was 23.0 mg/day. Notably, at week 24, superior spleen volume reduction was achieved by the selinexor combination, regardless of the ruxolitinib dose, including by patients receiving less than 15 mg of ruxolitinib per day.
More news about: Karyopharm Therapeutics Inc.
Jun 02, 2026, 08:48 ET OmniActive Study Shows enXtra Supports Sustained Energy for Wellness-Focused Adults
participants. Healthy men and women ages 18–40, all habitual caffeine consumers, received one of four interventions: enXtra 300 mg, caffeine 200 mg, enXtra 300 mg plus caffeine 200 mg, or placebo.Across the acute and sub-acute stages, enXtra demonstrated statistically significant improvements in alertness
More news about: OmniActive Health Technologies
Jun 02, 2026, 07:00 ET AWAKE CHOCOLATE FLIPS HOTEL TRADITION WITH FIRST-EVER "TURN UP" SERVICE
2–30*. Instead of chocolate at night, guests can request to wake up to a morning "Turn Up Service" cart delivery featuring AWAKE Crispy Bites, with 50mg of caffeine per Bite, alongside coffee, fresh fruit and other light bites, plus an energizing music and lighting shift to start the day right.The
More news about: AWAKE Chocolate
Jun 02, 2026, 04:19 ET Skyhawk Therapeutics gibt Zwölfmonats-Zwischenergebnisse der klinischen Phase-1/2-Studie zu SKY-0515 bei der Huntington-Krankheit bekannt
gewichteten Analysen zum natürlichen Krankheitsverlauf bei symptomatischen Patienten SKY-0515-Patienten erreichten bei der 9-mg-Dosis nach zwölf Monaten eine Reduktion des mutierten Huntingtin-Proteins (mHTT) um 69 % Das Unternehmen gibt außerdem bekannt,
More news about: Skyhawk Therapeutics
Jun 02, 2026, 04:00 ET AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
migraine."The approval of AQUIPTA is supported by data from the Phase 3 ECLIPSE study, which evaluated the efficacy, safety, and tolerability of AQUIPTA (60 mg) versus placebo for the acute treatment of migraine for a single attack and the consistency of effect across multiple attacks in adults with a history
More news about: AbbVie
Jun 01, 2026, 18:16 ET /C O R R E C T I O N -- Ranok Therapeutics/
follow-up demonstrated durable clinical benefit. Progression-free survival (PFS) data for the optimized 1200 mg QD cohort remain immature and continue to mature. In the pooled lower-dose cohorts (400–1000 mg QD), RNK08954 achieved a median PFS of 7.6 months (95% CI, 2.8–NR). Robust molecular responses were evidenced
More news about: Ranok Therapeutics
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
effect: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'. This medicinal product contains 0.04 mg of polysorbate 80 in each 1 mg vial and 0.2 mg in each 10 mg vial. Polysorbates may cause allergic reactions.ADVERSE
More news about: Amgen
Jun 01, 2026, 15:00 ET Fábrica de Nutrição Especializada da Danone completa 10 anos como referência global em segurança, qualidade e sustentabilidade
A unidade em Poços de Caldas (MG) registra um crescimento médio de 6% ao ano no volume produzido, alcança a marca de seis anos sem acidentes de trabalho e consolida-se com iniciativas de sustentabilidade inéditas no grupo Danone
More news about: Danone
Jun 01, 2026, 12:07 ET Solv Wellness Partners with Mia Syn, MS, RDN, to Help Women Navigate Menopause Supplements
GennaMD™, a urologist-recommended, clinical-strength cranberry UTI supplement made with verified 36 mg PAC from 100% soluble, pure cranberry juice extract for maximum defense against UTI-causing bacteria.
More news about: Solv Wellness®
Jun 01, 2026, 09:00 ET Qualia Launches New Clinically Tested Qualia Vitamin C+ To Advance How the Body Absorbs and Utilizes Vitamin C
mimic how the body evolved to absorb and utilize vitamin C, and the clinical results are extremely encouraging."Qualia Vitamin C+ delivers 500 mg of vitamin C from seven distinct sources, including liposomal PureWay-C® and chelated Nutra-C®, both selected for their superior bioavailability compared
More news about: Qualia Life Sciences